Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival in Selected Patients with Peritoneal Carcinomatosis from Abdominal and Pelvic Malignancies: Results of 21 Cases

Abstract

We evaluated the perioperative safety profile and efficacy of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy

Preoperative serum carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer

“…For example, some stage III and stage IV patients with CRC underwent curative surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) but some patients did not. Our previous studies demonstrated that HIPEC could improve the OS and quality of life of patients with CRC [20][21][22].…”

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center

“…Since 2004, we have adopted cytoreductive surgery (CRS) and HIPEC to treat selected PC patients from gastrointestinal and gynecological malignancies [19].This report summarizes our experience in 30 CRS and HIPEC procedures for the treatment of 28 gastric PC patients.…”

Cytoreductive surgery with intraperitoneal chemotherapy to treat pseudomyxoma peritonei at nonspecialized hospitals

“…Furthermore, these data are based on a limited number of cases from national referral hospitals in Western countries, but there are very few reports from Asian countries including Japan. 16,17 Thus it is generally unclear whether the Sugarbaker procedure can be performed at nonspecialized hospitals. [18][19][20] Moreover, since PMP is a rare condition and peritonectomy is an unusual procedure, the concept of the treatment may not be widely understood.…”